Altimmune Fast Track for Treatment of Non-Alcoholic Steatohepatitis (NASH)

 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its clinical program investigating pemvidutide for the treatment of NASH.

https://www.globenewswire.com/news-release/2023/10/26/2767385/0/en/Altimmune-Granted-Fast-Track-Designation-by-FDA-for-Pemvidutide-for-the-Treatment-of-Non-Alcoholic-Steatohepatitis-NASH.html